Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.

[1]  Joe Y. Chang,et al.  Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial , 2020, Journal for ImmunoTherapy of Cancer.

[2]  P. Baas,et al.  Synergizing systemic responses by combining immunotherapy with radiotherapy in metastatic non-small cell lung cancer: The potential of the abscopal effect. , 2020, Lung cancer.

[3]  E. Graves,et al.  Extracellular cGAMP is a cancer-cell-produced immunotransmitter involved in radiation-induced anticancer immunity , 2020, Nature Cancer.

[4]  J. Welsh,et al.  Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy , 2019, Journal of Immunotherapy for Cancer.

[5]  J. Aerts,et al.  Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.

[6]  M. Ahn,et al.  Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Jianying Zhou,et al.  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.

[8]  Joe Y. Chang,et al.  Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment , 2019, Front. Immunol..

[9]  A. Tafreshi,et al.  Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[10]  R. Emerson,et al.  Radiotherapy induces responses of lung cancer to CTLA-4 blockade , 2018, Nature Medicine.

[11]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[12]  T. Jiang,et al.  Combined Radiotherapy and Anti–PD‐L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  C. N. Coleman,et al.  DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity , 2017, Nature Communications.

[14]  R. Emerson,et al.  Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade , 2017, Clinical Cancer Research.

[15]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[16]  R. Weichselbaum,et al.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.

[17]  K. Schäkel,et al.  Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. , 2013, Cancer cell.

[18]  N. Kawashima,et al.  Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody , 2009, Clinical Cancer Research.

[19]  N. Kawashima,et al.  Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  N. Kawashima,et al.  Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. , 2004, International journal of radiation oncology, biology, physics.